Market research
300482.SHE Guangzhou Wondfo Biotech Co.,Ltd
SHE CNY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 24.68
- Dividend yield
- 1.4%
- Beta
- 0.83
Profile
Instrument facts
- Exchange
- SHE
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- CNE100002102
- Market cap
- 7B
- P/E ratio
- Not available
- Analyst target
- 24.68
- Dividend yield
- 1.4%
- Beta
- 0.83
About
About Guangzhou Wondfo Biotech Co.,Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China and internationally. The company offers rapid test kits for COVID-19, drug of abuse, tumor marker, infectious disease, fertility, blood/serum/plasma test, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease, as well as Finecare FIA Meter X2, a 16-channel fluorescence immunoassay analyzing system; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; blood gas biochemical analyzers and blood gas analyzers; molecular diagnostics platform; pathology straining system; and HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company was founded in 1992 and is based in Guangzhou, China.
Research context
Guangzhou Wondfo Biotech Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 300482.SHE discussion.
5 years, 6 months ago
Guangzhou Wondfo Biotech Co.,Ltd is currently in a long term downtrend where the price is trading 10.1% below its 200 day moving average.
From a valuation standpoint, the stock is 1.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.5.
Guangzhou Wondfo Biotech Co.,Ltd's total revenue sank by 1.6% to $638M since the same quarter in the previous year.
Its net income has dropped by 29.9% to $68M since the same quarter in the previous year.
Finally, its free cash flow fell by 19.4% to $62M since the same quarter in the previous year.
Based on the above factors, Guangzhou Wondfo Biotech Co.,Ltd gets an overall score of 1/5.